Treatment of Chronic Constipation: Current Pharmacologic Approaches and Future Directions

被引:96
作者
Tack, Jan [1 ]
Mueller-Lissner, Stefan [2 ]
机构
[1] Univ Hosp Leuven, Dept Gastroenterol, Div Gastroenterol, B-3000 Louvain, Belgium
[2] Humboldt Univ, Dept Internal Med, Berlin, Germany
关键词
PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; DOUBLE-BLIND; COLONIC TRANSIT; GLYCOL; 3350; EFFICACY; PRUCALOPRIDE; MULTICENTER; ELECTROLYTES; DISORDERS;
D O I
10.1016/j.cgh.2008.12.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Chronic constipation is a common condition that affects up to 27% of the population. Dietary and lifestyle measures are usually the first-line therapy, but if these fail to have an effect then a variety of prescription and consumer laxatives are available. Traditional laxatives include bulking agents, osmotic agents, stool softeners, and stimulants of the gastrointestinal tract. All have been found to be more effective than placebo at relieving symptoms of constipation, but these results have been obtained primarily in short (4-week) trials and no class of laxative has been shown to be superior to another. Traditional laxatives work in many, but not all, patients and some patients cannot cope with the side effects, unpleasant taste, the requirements of the dosing regimen, or the notion of dose increase. New enterokinetic agents that affect peristalsis through selective interaction with 5-hydroxytryptamine-4 receptors and novel agents acting on intestinal secretion could offer an alternative option for patients with chronic constipation who cannot get adequate relief from current laxatives.
引用
收藏
页码:502 / 508
页数:7
相关论文
共 67 条
[1]
ANDRESEN V, 2007, GASTROENTEROLOGY, V33, P61
[2]
[Anonymous], 2004, Chin J Dig Dis, V5, P134
[3]
[Anonymous], 2005, AM J GASTROENTEROL, V100, pS1, DOI [10.1111/j.1572-0241.2005.50613_1.x, DOI 10.1111/J.1572-0241.2005.50613_1.X]
[4]
Bengtsson Mariette, 2005, Gastroenterol Nurs, V28, P3, DOI 10.1097/00001610-200501000-00002
[5]
The treatment of chronic constipation in elderly people -: An update [J].
Bosshard, W ;
Dreher, R ;
Schnegg, JF ;
Büla, CJ .
DRUGS & AGING, 2004, 21 (14) :911-930
[6]
Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans [J].
Bouras, EP ;
Camilleri, M ;
Burton, DD ;
McKinzie, S .
GUT, 1999, 44 (05) :682-686
[7]
Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder [J].
Bouras, EP ;
Camilleri, M ;
Burton, DD ;
Thomforde, G ;
McKinzie, S ;
Zinsmeister, AR .
GASTROENTEROLOGY, 2001, 120 (02) :354-360
[8]
Burden of chronic constipation must include estimates of work productivity and activity impairment in addition to traditional healthcare utilization [J].
Bracco, A ;
Kahler, K .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10) :S233-S233
[9]
Systematic review on the management of chronic constipation in North America [J].
Brandt, LJ ;
Prather, CM ;
Quigley, EMM ;
Schiller, LR ;
Schoenfeld, P ;
Talley, NJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01) :S5-S22
[10]
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound [J].
Briejer, MR ;
Bosmans, JP ;
Van Daele, P ;
Jurzak, M ;
Heylen, L ;
Leysen, JE ;
Prins, NH ;
Schuurkes, JAJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 423 (01) :71-83